Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press990RESOLUTIONРЕЗОЛЮЦИИTactics of vinflunin therapy; determining the best supportive treatment for malignant neoplasms of the bladder, on a stage III–IVТактика применения препарат а винфлунин, определение наилучшей поддерживающей терапии при злокачественных новообразованиях мочевого пузыря III–IV стадии300920191531601620910201909102019https://oncourology.abvpress.ru/oncur/article/view/990

.

В г. Москве 8 февраля 2019 г. состоялось заседание Совета экспертов, организованное Российским обществом клинической онкологии по вопросам тактики применения препарата винфлунин и наилучшей поддерживающей терапии при неоперабельном местно-распространенном и метастатическом уротелиальном раке.

1. Bellmunt J., Théodore C., Demkov T. et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 2009;27(27):4454– 61. DOI: 10.1200/JCO.2008.20.5534.Bellmunt J., Théodore C., Demkov T. et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 2009;27(27):4454– 61. DOI: 10.1200/JCO.2008.20.5534.2. Retz M., de Geeter P., Goebell P.J. et al. Vinflunine in routine clinical practice for the treatment of advanced or metastatic urothelial cell carcinoma – data from a prospective, multicenter experience. BMC Cancer 2015;15:455. DOI: 10.1186/s12885-015-1434-3.Retz M., de Geeter P., Goebell P.J. et al. Vinflunine in routine clinical practice for the treatment of advanced or metastatic urothelial cell carcinoma – data from a prospective, multicenter experience. BMC Cancer 2015;15:455. DOI: 10.1186/s12885-015-1434-3.3. Medioni J., Di Palma M., Guillot A. et al. Efficacy and safety of Vinflunine for advanced or metastatic urothelial carcinoma in routine practice based on the French multi-centre CURVE study. BMC Cancer 2016;16:217. DOI: 10.1186/s12885-0162262-9.Medioni J., Di Palma M., Guillot A. et al. Efficacy and safety of Vinflunine for advanced or metastatic urothelial carcinoma in routine practice based on the French multi-centre CURVE study. BMC Cancer 2016;16:217. DOI: 10.1186/s12885-0162262-9.4. Pistamaltzian N., Tzannis K., Pissanidou V. et al. Treatment of relapsed urothelial bladder cancer with vinflunine: real-world evidence by the Hellenic Genitourinary Cancer Group. Anticancer Drugs 2016;27(1):48–53. DOI: 10.1097/CAD.0000000000000297.Pistamaltzian N., Tzannis K., Pissanidou V. et al. Treatment of relapsed urothelial bladder cancer with vinflunine: real-world evidence by the Hellenic Genitourinary Cancer Group. Anticancer Drugs 2016;27(1):48–53. DOI: 10.1097/CAD.0000000000000297.5. Holmsten K., Dohn L., Jensen N.V. et al. Vinflunine treatment in patients with metastatic urothelial cancer: a Nordic retrospective multicenter analysis. Oncol Lett 2016;12(2):1293–300. DOI: 10.3892/ol.2016.4775.Holmsten K., Dohn L., Jensen N.V. et al. Vinflunine treatment in patients with metastatic urothelial cancer: a Nordic retrospective multicenter analysis. Oncol Lett 2016;12(2):1293–300. DOI: 10.3892/ol.2016.4775.6. Hussain S.A., Ansari J., Huddart R. et al. VICTOR: Vinflunine in advanced metastatic transitional cell carcinoma of the urothelium: A retrospective analysis of the use of vinflunine in multi-centre real life setting as second line chemotherapy through Free of Charge Programme for patients in the UK and Ireland. Int J Oncol 2017;50(3):768–72. DOI: 10.3892/ijo.2017.3847.Hussain S.A., Ansari J., Huddart R. et al. VICTOR: Vinflunine in advanced metastatic transitional cell carcinoma of the urothelium: A retrospective analysis of the use of vinflunine in multi-centre real life setting as second line chemotherapy through Free of Charge Programme for patients in the UK and Ireland. Int J Oncol 2017;50(3):768–72. DOI: 10.3892/ijo.2017.3847.7. Passalacqua R., Lazzarelli S., Donini M. et al. Real-life clinical practice results with vinflunine in patients with relapsed platinumtreated metastatic urothelial carcinoma: an Italian multicenter study (MOVIE-GOIRC 01-2014). BMC Cancer. 2017;17(1):493. DOI: 10.1186/s12885017-3466-3.Passalacqua R., Lazzarelli S., Donini M. et al. Real-life clinical practice results with vinflunine in patients with relapsed platinumtreated metastatic urothelial carcinoma: an Italian multicenter study (MOVIE-GOIRC 01-2014). BMC Cancer. 2017;17(1):493. DOI: 10.1186/s12885017-3466-3.8. Castellano D., Puente J., de Velasco G. et at. Safety and effectiveness of vinflunine in patients with metastatic transitional cell carcinoma of the urothelial tract after failure of one platinum-based systemic therapy in clinical practice. BMC Cancer 2014;14:779. DOI: 10.1186/1471-240714-779.Castellano D., Puente J., de Velasco G. et at. Safety and effectiveness of vinflunine in patients with metastatic transitional cell carcinoma of the urothelial tract after failure of one platinum-based systemic therapy in clinical practice. BMC Cancer 2014;14:779. DOI: 10.1186/1471-240714-779.9. Bellmunt J., Choueiri T.K., Fougeray R. et al. Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol 2010;28(11):1850–5. DOI: 10.1200/JCO.2009.25.4599.Bellmunt J., Choueiri T.K., Fougeray R. et al. Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol 2010;28(11):1850–5. DOI: 10.1200/JCO.2009.25.4599.10. Balar A.V., Galsky M.D., Rosenberg J.E. et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet 2017;389(10064):67–76. DOI: 10.1016/S0140-6736(16)32455-2.Balar A.V., Galsky M.D., Rosenberg J.E. et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet 2017;389(10064):67–76. DOI: 10.1016/S0140-6736(16)32455-2.11. Bellmunt J., de Wit R., Vaughn D.J. et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 2017;376(11):1015–26. DOI: 10.1056/NEJMoa1613683.Bellmunt J., de Wit R., Vaughn D.J. et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 2017;376(11):1015–26. DOI: 10.1056/NEJMoa1613683.12. Fradet Y., Bellmunt J., Vaughn D.J. et al. Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up. Ann Oncol 2019;30(6):970–6. DOI: 10.1093/annonc/mdz127.Fradet Y., Bellmunt J., Vaughn D.J. et al. Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up. Ann Oncol 2019;30(6):970–6. DOI: 10.1093/annonc/mdz127.13. Bellmunt J., De Wit R., Vaughn D.J. et al. Keynote-045: фOpen-label, phase III study of pembrolizumab versus investigator’s choice of paclitaxel, docetaxel, or vinflunine for previously treated advanced urothelial cancer; Proceedings of the 2016 SITC Annual Meeting; National Harbor, MD, USA. 9–13 November 2016.Bellmunt J., De Wit R., Vaughn D.J. et al. Keynote-045: фOpen-label, phase III study of pembrolizumab versus investigator’s choice of paclitaxel, docetaxel, or vinflunine for previously treated advanced urothelial cancer; Proceedings of the 2016 SITC Annual Meeting; National Harbor, MD, USA. 9–13 November 2016.14. Powles T. IMvigor211: a phase III randomized study examining atezolizumab versus chemotherapy for platinum-treated advanced urothelial carcinoma. Presented at the Second Special Conference of the European Association for Cancer Research (EACR), the American Association for Cancer Research (AACR) and the Italian Cancer Society (SIC), in Florence, Italy. June, 2017.Powles T. IMvigor211: a phase III randomized study examining atezolizumab versus chemotherapy for platinum-treated advanced urothelial carcinoma. Presented at the Second Special Conference of the European Association for Cancer Research (EACR), the American Association for Cancer Research (AACR) and the Italian Cancer Society (SIC), in Florence, Italy. June, 2017.15. Sharma P., Retz M., Siefker-Radtke A. et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicenter, singlearm, phase 2 trial. Lancet Oncol 2017;18(3):312–22. DOI: 10.1016/S14702045(17)30065-7.Sharma P., Retz M., Siefker-Radtke A. et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicenter, singlearm, phase 2 trial. Lancet Oncol 2017;18(3):312–22. DOI: 10.1016/S14702045(17)30065-7.